Karlheinz Schmelig

Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions.

CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany.

Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany.

Chundsell Medicals AB develops and markets novel molecular diagnostics for the treatment of cancer. Its product measures the expression pattern of selected embryonic stem cell genes in prostate cancer core needle biopsies. The company was founded by Sunne Rosell and Chunde Li in 2007 and is headquartered in Solna, Sweden.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany.

Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany.